Connect with us

Technology

Peptide Synthesis Market: USD 2.59 Billion by 2031, Driven by Therapeutic Demand & Advanced Synthesis Technologies, Says Mordor Intelligence

Published

on

HYDERABAD, India, Aug. 18, 2026 /PRNewswire/ — According to the latest report by Mordor Intelligence, the peptide synthesis market size is estimated at USD 1.90 billion in 2026 and is projected to reach USD 2.59 billion by 2031, registering a CAGR of 6.39% during the forecast period (2026–2031). Market expansion is being driven by growing demand for peptide-based therapeutics, increasing pharmaceutical and biotechnology research activities, and continued advancements in peptide synthesis technologies that support drug discovery and commercial manufacturing. 

The peptide synthesis market continues to evolve as pharmaceutical and biotechnology companies expand investments in peptide-based drug development across chronic disease, oncology, metabolic disorders, and rare disease applications. Increasing clinical research activity and the growing pipeline of peptide therapeutics are strengthening demand for high-quality synthesis platforms, specialized reagents, and contract manufacturing capabilities. 

Solid-phase peptide synthesis continues to serve as a widely utilized production approach, while emerging enzymatic and cell-free synthesis methods are gaining attention for their ability to improve sustainability and reduce solvent consumption during manufacturing processes. 

Technological advancements are reshaping the competitive landscape. Automation, high-throughput synthesizers, advanced purification systems, and greener chemistry approaches are improving manufacturing efficiency while supporting increasingly complex peptide production. Artificial intelligence-assisted peptide design and expanded contract development and manufacturing capabilities are also contributing to faster research workflows and broader commercial opportunities across the industry. 

Peptide Synthesis Market Share by Region 

North America represents a significant share of the peptide synthesis market, supported by advanced pharmaceutical research infrastructure, strong biotechnology investment, and increasing development of peptide-based therapeutics. 

Europe holds a notable position in the market, driven by growing pharmaceutical innovation, increasing adoption of sustainable manufacturing approaches, and continued investment in life sciences research. 

Asia-Pacific is emerging as the fastest-growing region due to expanding pharmaceutical manufacturing capabilities, rising biotechnology investments, and increasing contract manufacturing activity across countries including China, India, Japan, and South Korea. 

Soumya Goud, Senior Research Manager, Mordor Intelligence, says, “The peptide synthesis market reflects sustained innovation across therapeutic development and manufacturing technologies. Mordor Intelligence applies structured research methodologies supported by cross-validated industry data and transparent analytical frameworks, providing decision-makers with balanced and dependable market intelligence.” 

Peptide Synthesis Market Trends & Forecast 

Growing Adoption of Advanced Peptide Manufacturing Technologies 

Pharmaceutical companies are increasingly utilizing automated synthesis platforms and advanced purification technologies to improve production efficiency, product quality, and manufacturing scalability. 

Rising Demand for Contract Manufacturing and Development Services 

Growing outsourcing across pharmaceutical and biotechnology companies is creating increased demand for specialized peptide synthesis services, GMP manufacturing capabilities, and scalable production solutions. 

Increasing Focus on Sustainable Peptide Synthesis 

Manufacturers are exploring greener chemistry approaches, enzymatic synthesis methods, and reduced-solvent manufacturing processes to improve sustainability while maintaining production quality. 

Peptide Synthesis Market Segmentation Overview 

By Technique

Solid-PhaseManual SPPS  Automated SPPS  Microwave-Assisted SPPS  Liquid-Phase  Batch LPPS  Continuous-Flow LPPS  Hybrid & Recombinant  Cell-Free/Enzymatic  

By Product Type  

Equipment  Peptide Synthesizers  Cleavage & Deprotection Systems  Purification (Prep-HPLC)  Lyophilizers  Reagents & Consumables  Amino-Acid Building Blocks  Resins  Coupling Reagents & Activators  Solvents  Enzymes  Other Reagents & Consumables  Services  Custom/Catalog Peptide Synthesis  GMP Peptide Manufacturing  Peptide Library Design  Post-translational Modification Services  

By End User  

Pharmaceutical & Biotechnology Companies  Peptide CDMOs & CROs  Academic & Research Institutes  Diagnostic Laboratories  Food & Nutraceutical Producers  Cosmetic Manufacturers  

By Geography  

North America  United States  Canada  Mexico  Europe  Germany  United Kingdom  France  Italy  Spain  Rest of Europe  Asia-Pacific  China  India  Japan  Australia  South Korea  Rest of Asia-Pacific  Middle East and Africa  GCC  South Africa  Turkey Rest of Middle East and Africa  South America  Brazil  Argentina   Rest of South America  

For a full breakdown of market dynamics, segmentation insights, regional analysis, and competitive landscape, access the details of the Mordor Intelligence report: https://www.mordorintelligence.com/industry-reports/peptide-synthesis-market?utm_source=prnewswire 

Peptide Synthesis Market Competitive Outlook 

The peptide synthesis market features specialized peptide manufacturers, pharmaceutical suppliers, life sciences companies, and contract manufacturing organizations focused on expanding production capabilities and improving manufacturing efficiency. Market participants are investing in automated synthesis technologies, advanced purification platforms, sustainable manufacturing approaches, and GMP-compliant production facilities to strengthen their competitive positions. 

Strategic capacity expansions, technology innovation, and growing partnerships across pharmaceutical research and commercial manufacturing continue to shape the competitive landscape as peptide-based therapeutics gain broader adoption. 

Major Companies in the Peptide Synthesis Market include: 

Merck KGaA Thermo Fisher Scientific Inc. GenScript Bachem Holding AG Biotage AB 

Check out related reports published by Mordor Intelligence: 

Consumer Genomics Market 
The consumer genomics market is estimated to grow from USD 2.96 billion in 2026 to USD 8.66 billion by 2031, registering a CAGR of 23.95% during the forecast period. Growth is supported by increasing consumer interest in personalized health insights, expanding availability of direct-to-consumer genetic testing, and growing awareness of genomics-based wellness and ancestry applications. 

Immune Repertoire Sequencing Market 
The immune repertoire sequencing market is projected to grow from USD 358.41 million in 2026 to USD 560.36 million by 2031, advancing at a CAGR of 9.35% during the forecast period. Market expansion is supported by increasing applications in immunology research, growing demand for advanced immune profiling, and the expanding use of sequencing technologies in therapeutic and diagnostic research. 

Medical Biomimetic Materials Market 
The medical biomimetic materials market is expected to increase from USD 20.66 billion in 2026 to USD 29.33 billion by 2031, registering a CAGR of 7.26% during the forecast period. Growth is driven by increasing demand for advanced materials that replicate biological structures and functions, alongside their expanding applications in tissue engineering, regenerative medicine, and medical devices. 

Know more about Mordor Intelligence:   

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.   

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.  

For any inquiries, please contact: 
media@mordorintelligence.com
https://www.mordorintelligence.com/contact-us 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/peptide-synthesis-market-usd-2-59-billion-by-2031–driven-by-therapeutic-demand–advanced-synthesis-technologies-says-mordor-intelligence-302853965.html

SOURCE Mordor Intelligence Private Limited

Continue Reading

Technology

Prospa research: Two in three Aussie SMEs want rewards on their bills, yet only 8% are cashing in on supplier payments

Published

on

By

New Prospa and YouGov research finds SMEs would put an average of nearly $9,400 a month through a rewards-enabled payment platform, while only 8% currently route B2B payments through platforms offering rewards

SYDNEY, Nov. 16, 2026 /PRNewswire/ — Australian small and medium businesses could be missing out on rewards from thousands of dollars in necessary business spending each month, as rising operating costs continue to put pressure on margins.

New research from Australian fintech Prospa and YouGov found 84% of Australian SMEs have experienced rising operational costs, while 80% say unavoidable expenses have squeezed their margins over the past 12 months.

With businesses already paying suppliers, bills and other operating costs, the findings suggest SMEs are increasingly looking for ways to get more value from spending they cannot avoid.

Two in three Australian SMEs would use a rewards-enabled payment platform if given the option, yet only 8% currently use one for B2B payments. SMEs said they would put an average of $9,398 a month through a platform that offered rewards.

Beau Bertoli, Co-Founder and Chief Revenue Officer at Prospa, said: “Every business has regular expenses that need to be paid, regardless of the economic environment. This research shows there is an opportunity for business owners to get more value from those everyday payments, rather than viewing them as simply a cost of doing business.

“Australian SMEs are looking for more value from the unavoidable costs of running a business. Two in three would put overheads through a rewards-enabled payment platform if given the option, yet only 8% currently route B2B payments through one. That gap shows rewards-enabled business payments remain a largely untapped opportunity.”

Most SMEs are not earning rewards on B2B payments

The research found Australian SMEs currently use several methods to earn value from business spending:

23% use a business card that earns points, cashback or rewards.14% negotiate rebates or loyalty benefits directly with suppliers.8% use a B2B payment platform that offers rewards.A further 20% are actively looking for ways to get value or rewards from money they already spend.

“The results show that rewards are already part of how some SMEs approach business spending, although the methods used differ,” Bertoli said.

“For some businesses, this means using rewards cards to get more value from everyday spending. Others are negotiating rebates with suppliers or routing B2B payments through platforms offering rewards. The opportunity is to give more SMEs practical ways to get greater value from spending that is already part of running their business.”

SMEs would put thousands through rewards-enabled business payments

The amount Australian SMEs would put through a rewards-enabled payment platform varied by business size and structure:

Across all SMEs surveyed, the average was $9,398 a month.Non-sole traders would put through an average of $14,682 a month.Sole traders would put through an average of $6,214 a month.One in five SMEs would put at least $10,000 of monthly business spending through one.

Non-sole traders were also more likely to actively look for value or rewards from money they already spend, at 27%, compared with 16% of sole traders.

“The level of interest naturally depends on the size and structure of each business, as every business faces its own unique expenses and payment volumes. That’s why it’s important to recognise that solutions need to be flexible to meet these diverse needs,” Bertoli said.

“We launched Prospa Rewards because small businesses told us they want their everyday spending to work harder. Business owners already have suppliers, bills and other operating costs to pay. This is about helping them get something back from the spending that is part of their business.”

About Prospa Rewards

The findings come following the launch of Prospa Rewards, a business rewards platform designed to help eligible Australian small businesses earn value from eligible business payments and transactions they already make.

Eligible customers can earn one Prospa Point for every $1 paid on eligible transactions. Prospa Points can be redeemed for selected business essentials and gift cards, or converted to Qantas Frequent Flyer Points.

Eligibility criteria, transaction requirements and redemption terms apply.

 

About Prospa

Prospa is a leading fintech committed to unleashing the potential of every small business in Australia and New Zealand. We do this by developing fast, flexible, stress-free lending solutions and financial management tools that help businesses thrive.

At Prospa, we’re deeply committed to making a meaningful impact on the small business community and on our people. Since 2012, Prospa has helped over 45,000 small businesses access over $5 billion in business funding, working with over 20,000 partners, including brokers, accountants, and aggregator partners, to help unlock business funding for their small business clients.

In addition to our commitment to supporting SMEs, Prospa has also been recognised for its workplace practices, culture, and values, culminating in our certification as a Great Place to Work in Australia, a Great Place to Work in Technology, and, in 2025, a Great Place to Work for Women.

For more information about Prospa, visit prospa.com

Methodology

All figures, unless otherwise stated, are from YouGov. Total sample size was 500 adults. Fieldwork was undertaken between 30th July – 13th August 2026. The survey was carried out online. The figures have been weighted and are representative of all Australian business owners and primary decision makers of businesses with fewer than 50 employees (aged 18+).

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/prospa-research-two-in-three-aussie-smes-want-rewards-on-their-bills-yet-only-8-are-cashing-in-on-supplier-payments-302937153.html

SOURCE Prospa

Continue Reading

Technology

Prospa research: Two in three Aussie SMEs want rewards on their bills, yet only 8% are cashing in on supplier payments

Published

on

By

New Prospa and YouGov research finds SMEs would put an average of nearly $9,400 a month through a rewards-enabled payment platform, while only 8% currently route B2B payments through platforms offering rewards

SYDNEY, Nov. 16, 2026 /PRNewswire/ — Australian small and medium businesses could be missing out on rewards from thousands of dollars in necessary business spending each month, as rising operating costs continue to put pressure on margins.

New research from Australian fintech Prospa and YouGov found 84% of Australian SMEs have experienced rising operational costs, while 80% say unavoidable expenses have squeezed their margins over the past 12 months.

With businesses already paying suppliers, bills and other operating costs, the findings suggest SMEs are increasingly looking for ways to get more value from spending they cannot avoid.

Two in three Australian SMEs would use a rewards-enabled payment platform if given the option, yet only 8% currently use one for B2B payments. SMEs said they would put an average of $9,398 a month through a platform that offered rewards.

Beau Bertoli, Co-Founder and Chief Revenue Officer at Prospa, said: “Every business has regular expenses that need to be paid, regardless of the economic environment. This research shows there is an opportunity for business owners to get more value from those everyday payments, rather than viewing them as simply a cost of doing business.

“Australian SMEs are looking for more value from the unavoidable costs of running a business. Two in three would put overheads through a rewards-enabled payment platform if given the option, yet only 8% currently route B2B payments through one. That gap shows rewards-enabled business payments remain a largely untapped opportunity.”

Most SMEs are not earning rewards on B2B payments

The research found Australian SMEs currently use several methods to earn value from business spending:

23% use a business card that earns points, cashback or rewards.14% negotiate rebates or loyalty benefits directly with suppliers.8% use a B2B payment platform that offers rewards.A further 20% are actively looking for ways to get value or rewards from money they already spend.

“The results show that rewards are already part of how some SMEs approach business spending, although the methods used differ,” Bertoli said.

“For some businesses, this means using rewards cards to get more value from everyday spending. Others are negotiating rebates with suppliers or routing B2B payments through platforms offering rewards. The opportunity is to give more SMEs practical ways to get greater value from spending that is already part of running their business.”

SMEs would put thousands through rewards-enabled business payments

The amount Australian SMEs would put through a rewards-enabled payment platform varied by business size and structure:

Across all SMEs surveyed, the average was $9,398 a month.Non-sole traders would put through an average of $14,682 a month.Sole traders would put through an average of $6,214 a month.One in five SMEs would put at least $10,000 of monthly business spending through one.

Non-sole traders were also more likely to actively look for value or rewards from money they already spend, at 27%, compared with 16% of sole traders.

“The level of interest naturally depends on the size and structure of each business, as every business faces its own unique expenses and payment volumes. That’s why it’s important to recognise that solutions need to be flexible to meet these diverse needs,” Bertoli said.

“We launched Prospa Rewards because small businesses told us they want their everyday spending to work harder. Business owners already have suppliers, bills and other operating costs to pay. This is about helping them get something back from the spending that is part of their business.”

About Prospa Rewards

The findings come following the launch of Prospa Rewards, a business rewards platform designed to help eligible Australian small businesses earn value from eligible business payments and transactions they already make.

Eligible customers can earn one Prospa Point for every $1 paid on eligible transactions. Prospa Points can be redeemed for selected business essentials and gift cards, or converted to Qantas Frequent Flyer Points.

Eligibility criteria, transaction requirements and redemption terms apply.

 

About Prospa

Prospa is a leading fintech committed to unleashing the potential of every small business in Australia and New Zealand. We do this by developing fast, flexible, stress-free lending solutions and financial management tools that help businesses thrive.

At Prospa, we’re deeply committed to making a meaningful impact on the small business community and on our people. Since 2012, Prospa has helped over 45,000 small businesses access over $5 billion in business funding, working with over 20,000 partners, including brokers, accountants, and aggregator partners, to help unlock business funding for their small business clients.

In addition to our commitment to supporting SMEs, Prospa has also been recognised for its workplace practices, culture, and values, culminating in our certification as a Great Place to Work in Australia, a Great Place to Work in Technology, and, in 2025, a Great Place to Work for Women.

For more information about Prospa, visit prospa.com

Methodology

All figures, unless otherwise stated, are from YouGov. Total sample size was 500 adults. Fieldwork was undertaken between 30th July – 13th August 2026. The survey was carried out online. The figures have been weighted and are representative of all Australian business owners and primary decision makers of businesses with fewer than 50 employees (aged 18+).

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/prospa-research-two-in-three-aussie-smes-want-rewards-on-their-bills-yet-only-8-are-cashing-in-on-supplier-payments-302937153.html

SOURCE Prospa

Continue Reading

Technology

The Pan-Mass Challenge Exceeds 2026 Fundraising Goal with Record-Breaking $80 Million Gift Fueling Lifesaving Research at Dana-Farber Cancer Institute

Published

on

By

With its largest gift ever, the world’s most successful athletic fundraiser continues to shatter fundraising records at a time when cancer research needs support most

BOSTON, Nov. 15, 2026 /PRNewswire/ — The Pan-Mass Challenge (PMC), a bike-a-thon which has raised more money for charity than any other single athletic fundraising event in the world, today presented a record-breaking $80 million gift to Dana-Farber Cancer Institute, one of the nation’s top three cancer hospitals. Presented at a celebratory brunch at Rochambeau in Boston, this gift brings the PMC’s total contribution to Dana-Farber’s mission to more than $1.2 billion.

For the 20th consecutive year, 100 percent of every rider-raised dollar goes directly to Dana-Farber. Powered by thousands of riders and volunteers from across the world, every dollar raised helps fuel groundbreaking cancer research, lifesaving treatments, and patient care.

“$80 million isn’t just a number. It represents the next clinical trial, the next breakthrough, the next life saved, and the next patient who gets to ring the bell at the end of treatment,” said Billy Starr, PMC founder and chairman. “Now, more than ever, our riders, volunteers, donors, and corporate partners understood exactly what was at stake. They didn’t just meet the moment, they rode right past it. I’ve never been prouder of this community, and I’ve never been more confident that the cures we ride for are within reach.”

The record-breaking gift arrives at a pivotal moment in the nation. While federal research support and grant approval rates are shrinking, cancer rates continue to climb, with more than 20 million new cancer cases projected worldwide in 2026 alone. The PMC’s sustained giving is one of the most essential forces keeping transformative research at Dana-Farber moving forward.

“We are immensely grateful for the PMC’s longstanding support of Dana-Farber,” said Benjamin L. Ebert, MD, PhD, president and CEO of Dana-Farber Cancer Institute and PMC rider. “This unprecedented gift is an important milestone and will be used to shape the future of cancer care and research at Dana-Farber. I am honored to be one of thousands of committed PMC riders and volunteers who have played a role in making a big impact.”

The PMC is Dana-Farber’s single largest contributor, accounting for 67 percent of revenue for the Jimmy Fund, Dana-Farber’s community fundraising arm. But the most significant measure of the PMC’s funding is found in the discoveries that bring new hope to patients and families facing cancer. PMC support helped drive some of Dana-Farber’s most significant recent breakthroughs, including the discovery of menin inhibitors, the improvement of multi-cancer early detection, and the development of new types of cell therapies such as CAR-T cell therapy and tumor-infiltrating lymphocyte (TIL) therapy.

The unprecedented gift reflects a full year of riding and fundraising. In addition to the flagship PMC weekend, crucial funding was supported by the PMC’s further spokes in the wheel, including PMC Winter Cycle, an indoor spin event at Fenway Park; PMC Unpaved, a gravel bike ride; and PMC Kids Rides, mini bike-a-thons for children ages 2 to 15.

The PMC is co-presented by the Red Sox Foundation® and M&T Bank. To learn more, get involved, or donate, visit www.pmc.org.

About the Pan-Mass Challenge
The Pan-Mass Challenge (PMC) is a bike-a-thon that today raises more money for charity than any other single athletic fundraising event in the world. Founded in 1980 by Billy Starr – who remains the event’s founder & chairman, an annual cyclist, and a fundraiser – the PMC has raised $1.2 billion for Dana-Farber Cancer Institute through the Jimmy Fund. As Dana-Farber’s single largest contributor, the organization generates 67 percent of the Jimmy Fund’s annual revenue. 100 percent of every rider-raised dollar goes directly to fueling cancer research and treatment at Dana-Farber. In addition to its two-day bike-a-thon across Massachusetts, the PMC is powered by further “spokes in the wheel,” with initiatives including the PMC Winter Cycle, an indoor spin event, PMC Unpaved, a gravel bike ride, and PMC Kids Rides, mini bike-a-thons for children ages 2 to 15. The PMC attracts riders and volunteers from 44 states and eight countries and over 300,000 individual donors. Across events, the PMC has successfully melded support from committed cyclists, volunteers, corporate sponsors, and individual donors, all of whom are essential to the PMC’s goal and model: to attain maximum fundraising efficiency while increasing its annual gift. The PMC’s aspiration is to provide Dana-Farber’s doctors and researchers with the necessary resources to discover cures for all cancers. For more information, visit www.pmc.org.

About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is a global leader in cancer research and care, with a mission to reduce the burden of cancer through scientific discovery, clinical excellence, education, community engagement and advocacy. Dana-Farber is dedicated to a unique and equal balance of cancer research and care, offering more than 1,200 clinical trials and translating the results of discovery into new treatments for patients locally and around the world. U.S. News & World Report recognized Dana-Farber Brigham Cancer Center as the Best Hospital for Cancer in Massachusetts and number three in the nation, and Dana-Farber Boston Children’s Cancer and Blood Disorders Center as the Best Children’s Hospital for Cancer in the country, making Dana-Farber the only hospital in the country among the top three for both adult and pediatric cancer care. It is a federally designated Comprehensive Cancer Center and a principal teaching affiliate of Harvard Medical School.

About the Jimmy Fund
The Jimmy Fund is comprised of community-based fundraising events and other programs that, solely and directly, benefit Dana-Farber Cancer Institute’s lifesaving mission to provide compassionate patient care and groundbreaking cancer research for children and adults. Since 1948, the generosity of millions of people has helped the Jimmy Fund save countless lives and reduce the burden of cancer for patients and families worldwide.

The Jimmy Fund is proud of its longstanding partnerships with the Boston Red Sox and the Red Sox Foundation, the Boston Athletic Association, the Massachusetts Chiefs of Police Association, the Pan-Mass Challenge, and Variety Children’s Charity of New England, which was instrumental in the Jimmy Fund’s founding. Follow the Jimmy Fund on Facebook, Instagram, LinkedIn, TikTok, and X: @TheJimmyFund

Contacts

Jenna Lehan, on behalf of the PMC
Jenna@hollywoodagency.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-pan-mass-challenge-exceeds-2026-fundraising-goal-with-record-breaking-80-million-gift-fueling-lifesaving-research-at-dana-farber-cancer-institute-302939737.html

SOURCE Pan-Mass Challenge

Continue Reading

Trending